Columbus Macro LLC Buys 6,120 Shares of Johnson & Johnson (NYSE:JNJ)

Columbus Macro LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 59.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,501 shares of the company’s stock after purchasing an additional 6,120 shares during the quarter. Columbus Macro LLC’s holdings in Johnson & Johnson were worth $2,386,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $31,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $40,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JNJ shares. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners reduced their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Trading Down 0.8 %

NYSE:JNJ opened at $153.46 on Friday. The stock has a market capitalization of $369.47 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a 50 day moving average of $147.49 and a 200 day moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.23%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.